Pour en savoir plus
ISSN: 2950-2128
Format: e-only
Marque / éditeur: MASSON
Copyright : © Elsevier Masson SAS
couverture
Innovative Practice in Breast Health

Editor-in-Chief

Pr. Carole M. Mathelin, MD, PhD, Strasbourg, France

Associate Editors-in-chief

Tolga Ozmen, MD, Boston, MA, USA, Guosheng Ren, Chongqing, China, Sébastien Moliere, MD, Strasbourg, France, Nicolas Taris, PhD, Strasbourg, France

Editorial Board

Khalid Alghamdi, MD, Jeddah, Saudi Arabia, Anne-Sophie Azuar, MD, Grasse, France, Susie Brousse, MD, PhD, Rennes, France, Foucauld Chamming's, Md, PhD, Bordeaux, France, Christophe Cordier, PhD, Lausanne, Switzerland, Yann Delpech, Nice, France, Darius Dian, Prof. Dr. med. Dr. rer. hum. Biol, MBA, Munich, Germany, Shigeru Imoto, MD, PhD, Mitaka, Japan, Cary Kaufman, MD, Washington, USA, Meriem Koual, MD, PhD, Paris, France, Hongyuan Li, Chongqing, China, Mauricio Magalhães Costa, MD, MSc, PhD, Rio de Janeiro, Brazil, Alexander Mundinger, Prof. Dr. med., Münster, Germany, Vahit Özmen, MD, PhD, Istanbul, Turkey, Tadeusz Pienkowski, MD, PhD, Warsaw, Poland, Schlomo Schneebaum, MD, Tel Aviv, Israel, Mickael Tardy, PhD, Nantes, France, Catherine Tomasetto, PhD, Strasbourg, France, Catherine Uzan, Md, PhD, Paris, France, Charlotte Vaysse, MD, PhD, Toulouse, France, Jian Ying, Tianjin, China

Managing Editor : Albert Moussaron, PhD, Strasbourg, France

The aim of this journal is to provide a platform for the sharing of new knowledge and research related to evaluation of applications of new technologies in the field of breast diseases. The journal seeks to promote the development and understanding of the latest advances in artificial intelligence, data science and data omics, telemedicine, image-assisted surgery, connected objects and telemedicine, prediction, personalized medicine and simulation in the field of breast cancer and other breast pathologies.

This journal will publish high quality peer-reviewed original research, review articles, editorials, case reports (proof of concept of innovative applications of artificial intelligence-related technologies), and perspectives that encompass the evaluation and application of innovative technologies in the treatment, prevention, diagnosis and management of breast pathologies.

The journal welcomes research from all relevant disciplines, provided that it involves artificial intelligence-related technologies and breast diseases, including but not limited to surgery, imaging, medical oncology, radiation oncology, pathology, genetics, epidemiology, public health, nursing and allied health sciences, psychology, sociology, education, economic and health policy and management.

The scope of the journal includes but is not limited to:

  • Clinical trials and translational research regarding artificial intelligence-related technologies and breast pathologies
  • Artificial intelligence and its application to data science, data omics, telemedicine and breast pathologies
  • Algorithms for analyzing large-scale data sets for breast cancer diagnosis, prognosis and treatment; and also patient experience and patient-related outcomes
  • Machine learning and deep learning approaches for breast imaging and surgery
  • Telemedicine and telehealth applications for the management and screening of breast cancer and breast diseases
  • Big data and data omics applications in breast cancer research, diagnosis and treatment

The aim of this journal is to provide a platform for the sharing of new knowledge and research related to evaluation of applications of new technologies in the field of breast diseases. The journal seeks to promote the development and understanding of the latest advances in artificial intelligence, data science and data omics, telemedicine, image-assisted surgery, connected objects and telemedicine, prediction, personalized medicine and simulation in the field of breast cancer and other breast pathologies.

This journal will publish high quality peer-reviewed original research, review articles, editorials, case reports (proof of concept of innovative applications of artificial intelligence-related technologies), and perspectives that encompass the evaluation and application of innovative technologies in the treatment, prevention, diagnosis and management of breast pathologies.

The journal welcomes research from all relevant disciplines, provided that it involves artificial intelligence-related technologies and breast diseases, including but not limited to surgery, imaging, medical oncology, radiation oncology, pathology, genetics, epidemiology, public health, nursing and allied health sciences, psychology, sociology, education, economic and health policy and management.

The scope of the journal includes but is not limited to:

  • Clinical trials and translational research regarding artificial intelligence-related technologies and breast pathologies
  • Artificial intelligence and its application to data science, data omics, telemedicine and breast pathologies
  • Algorithms for analyzing large-scale data sets for breast cancer diagnosis, prognosis and treatment; and also patient experience and patient-related outcomes
  • Machine learning and deep learning approaches for breast imaging and surgery
  • Telemedicine and telehealth applications for the management and screening of breast cancer and breast diseases
  • Big data and data omics applications in breast cancer research, diagnosis and treatment
Lire la suite Masquer

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.